BR112013026355A2 - compostos de pirazolo[3,4-b]piridina tri- e tetracíclicos como agente antineoplásico - Google Patents
compostos de pirazolo[3,4-b]piridina tri- e tetracíclicos como agente antineoplásicoInfo
- Publication number
- BR112013026355A2 BR112013026355A2 BR112013026355A BR112013026355A BR112013026355A2 BR 112013026355 A2 BR112013026355 A2 BR 112013026355A2 BR 112013026355 A BR112013026355 A BR 112013026355A BR 112013026355 A BR112013026355 A BR 112013026355A BR 112013026355 A2 BR112013026355 A2 BR 112013026355A2
- Authority
- BR
- Brazil
- Prior art keywords
- antineoplastic agent
- tetracyclic
- pyrazolo
- tri
- pyridine compounds
- Prior art date
Links
- 229940034982 antineoplastic agent Drugs 0.000 title abstract 3
- 239000002246 antineoplastic agent Substances 0.000 title abstract 3
- 150000005230 pyrazolo[3,4-b]pyridines Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1153200A FR2974088A1 (fr) | 2011-04-12 | 2011-04-12 | Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux |
| PCT/EP2012/056637 WO2012140114A1 (en) | 2011-04-12 | 2012-04-12 | Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013026355A2 true BR112013026355A2 (pt) | 2016-12-27 |
Family
ID=44512344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013026355A BR112013026355A2 (pt) | 2011-04-12 | 2012-04-12 | compostos de pirazolo[3,4-b]piridina tri- e tetracíclicos como agente antineoplásico |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9085575B2 (https=) |
| EP (1) | EP2697222A1 (https=) |
| JP (1) | JP5972964B2 (https=) |
| KR (1) | KR20140023341A (https=) |
| CN (1) | CN103534254B (https=) |
| AR (1) | AR085987A1 (https=) |
| AU (1) | AU2012241891B2 (https=) |
| BR (1) | BR112013026355A2 (https=) |
| CA (1) | CA2832704A1 (https=) |
| FR (1) | FR2974088A1 (https=) |
| MX (1) | MX2013011854A (https=) |
| RU (1) | RU2013148922A (https=) |
| TW (1) | TWI560187B (https=) |
| WO (1) | WO2012140114A1 (https=) |
| ZA (1) | ZA201307783B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| ES2704744T3 (es) | 2012-06-13 | 2019-03-19 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| US10053477B2 (en) | 2014-07-04 | 2018-08-21 | Qilu Pharmaceutical Co., Ltd. | Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide |
| CN104447736B (zh) * | 2014-10-14 | 2016-06-08 | 雅安职业技术学院 | 一种veranamine的合成方法 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9974784B2 (en) * | 2015-01-21 | 2018-05-22 | The Texas A&M University System | Inhibitors of activin-like receptor kinases |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| MX373169B (es) | 2015-02-20 | 2020-04-24 | Incyte Holdings Corp | Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr). |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
| MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3179671A1 (en) * | 2020-08-07 | 2022-02-10 | Abm Therapeutics Corporation | Kinase inhibitors and uses thereof |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN118891264A (zh) | 2022-08-01 | 2024-11-01 | 齐鲁制药有限公司 | 螺环胺类芳基磷氧化合物的晶型及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4836788B2 (ja) * | 2003-07-23 | 2011-12-14 | エグゼリクシス， インコーポレイテッド | 未分化リンパ腫キナーゼ変調因子及びその使用法 |
| MX2008002165A (es) * | 2005-08-16 | 2008-04-29 | Irm Llc | Compuestos y composiciones como inhibidores de la proteina cinasa. |
| CN101525497B (zh) * | 2008-03-06 | 2012-07-04 | 中国科学院理化技术研究所 | 吡唑啉吡啶并苯并香豆素荧光染料衍生物及其合成方法和用途 |
| US20100113415A1 (en) * | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
-
2011
- 2011-04-12 FR FR1153200A patent/FR2974088A1/fr active Pending
-
2012
- 2012-04-11 TW TW101112790A patent/TWI560187B/zh not_active IP Right Cessation
- 2012-04-11 AR ARP120101242A patent/AR085987A1/es not_active Application Discontinuation
- 2012-04-12 EP EP12714688.4A patent/EP2697222A1/en not_active Withdrawn
- 2012-04-12 RU RU2013148922/04A patent/RU2013148922A/ru not_active Application Discontinuation
- 2012-04-12 WO PCT/EP2012/056637 patent/WO2012140114A1/en not_active Ceased
- 2012-04-12 CA CA2832704A patent/CA2832704A1/en not_active Abandoned
- 2012-04-12 MX MX2013011854A patent/MX2013011854A/es not_active Application Discontinuation
- 2012-04-12 CN CN201280023479.XA patent/CN103534254B/zh not_active Expired - Fee Related
- 2012-04-12 AU AU2012241891A patent/AU2012241891B2/en not_active Ceased
- 2012-04-12 JP JP2014504312A patent/JP5972964B2/ja not_active Expired - Fee Related
- 2012-04-12 KR KR1020137029401A patent/KR20140023341A/ko not_active Withdrawn
- 2012-04-12 US US14/111,098 patent/US9085575B2/en not_active Expired - Fee Related
- 2012-04-12 BR BR112013026355A patent/BR112013026355A2/pt not_active IP Right Cessation
-
2013
- 2013-10-18 ZA ZA2013/07783A patent/ZA201307783B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140031362A1 (en) | 2014-01-30 |
| AR085987A1 (es) | 2013-11-13 |
| EP2697222A1 (en) | 2014-02-19 |
| ZA201307783B (en) | 2015-01-28 |
| CN103534254B (zh) | 2015-11-25 |
| HK1190397A1 (zh) | 2014-07-04 |
| JP2014510774A (ja) | 2014-05-01 |
| RU2013148922A (ru) | 2015-05-20 |
| TW201247665A (en) | 2012-12-01 |
| MX2013011854A (es) | 2013-11-01 |
| CN103534254A (zh) | 2014-01-22 |
| JP5972964B2 (ja) | 2016-08-17 |
| TWI560187B (en) | 2016-12-01 |
| WO2012140114A1 (en) | 2012-10-18 |
| US9085575B2 (en) | 2015-07-21 |
| AU2012241891B2 (en) | 2016-06-16 |
| KR20140023341A (ko) | 2014-02-26 |
| CA2832704A1 (en) | 2012-10-18 |
| FR2974088A1 (fr) | 2012-10-19 |
| AU2012241891A1 (en) | 2013-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013026355A2 (pt) | compostos de pirazolo[3,4-b]piridina tri- e tetracíclicos como agente antineoplásico | |
| PH12014502041A1 (en) | Heterocyclyl compounds as mek inhibitors | |
| BR112014002245A2 (pt) | derivados de piridin-2(1h)-ona como inibidores de jak | |
| EA201300620A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ JAK | |
| MX377635B (es) | Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| EA201492204A1 (ru) | Нуклеозиды на основе урацила и спирооксетана | |
| UA113651C2 (xx) | Макроциклічні пурини для лікування вірусних інфекцій | |
| CR20130617A (es) | Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
| MX336214B (es) | Derivados de pirrolotriazinona como inhibidores de pi3k. | |
| EA201591195A1 (ru) | Новые хинолоновые производные | |
| HK1211027A1 (en) | Pyrrolotriazinone derivatives as pi3k inhibitors | |
| BR112013019160A2 (pt) | novos compostos, composição farmacêutica, uso, processos e métodos | |
| BR112014031091A2 (pt) | Derivados de piperidina para agonista de gpr119 | |
| WO2012135615A3 (en) | Enopeptins, uses thereof, and methods of synthesis thereto | |
| EA201400064A1 (ru) | Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб | |
| WO2012099952A3 (en) | Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-ht6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia | |
| PH12015502717B1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| EA201400786A1 (ru) | Карбоциклические нуклеозиды, их фармацевтическое применение и композиции | |
| UA111851C2 (uk) | Сполуки піридазинону та їх використання як інгібіторів daao | |
| TN2013000146A1 (en) | Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |